Toxicology Lerters, 51 (1990) 227-231
227
Elsevier
TOXLET
023 12
Inhibitory effects of carcinogenic tryptophan pyrolysis products on phytohemagglutinin-induced blast transformation of human lymphocytes
Hiroyuki
Yanagisawa*
and Osamu Wada
Department of Hygiene und Preventive Medicine, Faculty of Medicine, University ofTokyo, Tokyo (Japan) (Received
5 October
(Revision
received
(Accepted
1989) 11 October
13 November
1989)
1989)
Key words: Carcinogenic
heterocyclic
amines: Phytohemagglutinin;
Blast transformation
of human
lymphocytes
SUMMARY In order to evaluate human
the effect of carcinogenic
cells, we examined
methylimidazo
[4,5:jjquinoline
dipyrido[l.2-u:3’,2’-d]imidazole 3-amino-1-methyl-SH-pyrido[4,3-h] formation
induced
I .O-10 PM, respectively. inhibitory
(Glu-P-2).
The concentrations
However,
effect on lymphocyte
on human (PHA).
stimulated of Trp-P-l
the other carcinogenic mitogenesis
on the stimulussreaction
heterocychc
lymphocyte
added at the final concentration
2-amino-3-
Both Trp-P-l
and Trp-P-2
and Trp-P-2
causing amines
exhibited of
50% inhibition examined
amines
culture medium
an inhibi-
I .O-5.0 and were 3.1 and
did not show any
of 10 PM. Viabilities heterocyclic
of 10 PM to the lymphocyte
and
(4 x lo5 cells/ml) blast trans-
heterocyclic
even at a final concentration
2-amino-
(Trp-P-l)
by PHA at the final concentration
cytes were more than 90% (n = 3 x 5) when 5 kinds of carcinogenic respectively
system of
amines including
3.amino-1,4-dimethyl-SH-pyrido[4,3-blindole
indole (Trp-P-2) proliferation
amines
1,2-u:3’,2’-d)imidazole (Glu-P-l),
(IQ), 2-amino-6_methyldipyrido[
by 0.125% phytohemagglutinin
tory effect on the lymphocyte 5.1 PM, respectively.
heterocyclic
the effect of 5 kinds of carcinogenic
of lympho-
(0.1 ml) were
(4 x IO5 cells/O.9
ml).
INTRODUCTION
The diet is recently regarded as one of the most important factors related to the incidence of human cancers [l]. Various kinds of mutagenic heterocyclic amines have * Current address and correspondence: H. Yanagisawa, University
School of Medicine,
0378-4274/90/$3.50
Renal
Division,
Box 8126, 660 South Euclid Avenue,
@ 1990 Elsevier Science Publishers
Internal
Medicine,
Washington
St. Louis, MO 63110, U.S.A.
B.V. (Biomedical
Division)
22x
been reported to be present in cooked foods, cigarette smoke condensate and fried egg patties [224]. The majority of those mutagens have shown carcinogenic effects in animal experiments [2], and are now supposed By using the dialysate and plasma of patients correlation
between
human
cancers
to be dietary with uremia,
and carcinogenic
carcinogens. we have examined
heterocyclic
amines.
the
We re-
ported that several carcinogenic heterocyclic amines were present in the dialysate and plasma of patients with uremia, and that humans were actually exposed to several carcinogenic heterocyclic amines including 3-amino-l,4-dimethyl-5H-pyrido[4,3-h]indole (Trp-P-l) and 3-amino-I-methyl-5H-pyrido[4,3-hlindole (Trp-P-2) [559]. More recently, we reported that carcinogenic tryptophan pyrolysis products inhibited cycle-oxygenase activity in human platelet aggregation induced by ADP, collagen and sodium arachidonate [lo]. In this investigation, in order to investigate further effects of carcinogenic heterocyclic amines on the stimulus-reaction system of human cells, we examined the influence of 5 kinds of carcinogenic heterocyclic amines on human lymphocyte blast transformation induced by phytohemagglutinin (PHA). As a result, we demonstrated that among the 5 carcinogenic heterocyclic amines only tryptophan pyrolysis products showed an inhibitory effect on lymphocyte mitogenesis. MATERIALS
AND METHODS
Trp-P- 1 acetate, Trp-P-2 acetate, 2-amino-6_methyldipyrido[ 1,2-a:3’,2’-dimidazole (Glu-P-l), 2-aminodipyrido[l,2-a:3’,2’-d]imidazole (Glu-P-2) and 2-amino-3methylimidazo[4,5Tflquinoline (IQ) were purchased from Wako Pure Chemical Industries (Osaka, Japan). Heparin was obtained from Novo Industri A/S (Copenhagen, Denmark). The lymphocyte blast transformation research kit (Japan Immunoresearch Laboratories Fluorescence Blast Transformation Test: JIMRO FBT) was kindly provided by Otsuka Assay Laboratories (Tokushima, Japan). Preparation and culture of human lymphocytes and the lymphocyte blast transformation test by PHA were performed by using JIMRO FBT. Five healthy male volunteers were studied. The ages of the healthy males ranged from 26 to 32 years (mean 29.4 + 2.4 (SD) years, n = 5). Peripheral blood lymphocytes were prepared from heparinized blood of 5 subjects by Ficoll-Conray (Otsuka Assay Laboratories) gradient centrifugation. The lymphocytes separated were washed with 50 mM phosphate-buffered saline (PBS) 3 times and suspended at the concentration of 1 x IO6 cells/ml in RPM1 1640 containing 10% fetal calf serum (FCS) (culture medium). Finally, 5 kinds of carcinogenic heterocyclic amines (IQ, Glu-P- I, Glu-P-2. Trp-P-l and Trp-P-2) were adjusted to various concentrations (10, 25, 50, 100 PM) in the culture medium. The lymphocyte suspension (4 x IO5 cells/O.4 ml) was divided into each well of 24-well cultured plates, and then preincubated for 15 min with 100 ,uI of various concentrations of carcinogenic heterocyclic amine solutions or 100 ,~l of the culture medi-
229
urn in the case of the control. by adding
The preincubated
500 ,~l of 0.125% PHA in the culture
samples
were cultured
medium
for 72 h at 37°C with 5%
in triplicate
CO2 in a humidified atmosphere. The lymphocyte blast transformation test by PHA was carried out by using ethidium bromide fluorescence assays based on JIMRO FBT [11,12]. The 72-h cultured lymphocytes were transferred into new plastic tubes from each well of the culture plates and then centrifuged at 2500 rpm at room temperature for 10 min. After the removal of supernatant from the tubes, 2 ml of 0.125% sodium dodecylsulfate (SDS) was added to each tube, and the tubes were then allowed to stand for 30 min at room temperature. Next, each tube was allowed to stand for 15 min in the presence of 2 ml ethidium bromide (7.5 pg/ml). Finally, lymphocyte reactivity to PHA was determined by fluorescence intensities (excitation at 525 nm, emission at 600 nm) using a Hitachi fluorescence spectrophotometer 650-60 (Hitachi, Tokyo, Japan). The percent inhibition of lymphocyte mitogenesis by carcinogenic heterocyclic amines was calculated with the formula below: X-Y % Inhibition =x-z x 100, where X = fluorescence intensities of lymphocytes stimulated by PHA, Y = fluorescence intensities of lymphocytes by PHA in the presence of carcinogenic heterocyclic amines, and Z = fluorescence intensities of lymphocytes without stimulation by PHA. Percent inhibition was expressed as a mean value of triplicate measurements. The mean and SD were calculated on the basis of 5 experiments. RESULTS
AND DISCUSSION
The optimal concentration of PHA was determined in the range of 0.01-l .O% (0.5 ml) by using lymphocytes (4 x lo5 cells/O.5 ml) from 3 healthy male volunteers. The strongest fluorescence intensities of lymphocytes stimulated by PHA were obtained at the concentration of 0.084.15%. The PHA concentration of 0.125% was therefore used for the stimulation of lymphocytes, as described previously [12]. Viabilities of lymphocytes were checked by adding trypan blue to an aliquot of human lymphocytes (4 x IO5 cells/O.9 ml) cultured for 72 h with 5 kinds of 100 ,uM carcinogenic heterocyclic amines (0.1 ml) using a phase-difference microscope. Viabilities of lymphocytes examined were more than 90% (n = 3 x 5) in all cases. To investigate the effect of carcinogenic heterocyclic amines on the stimulus-reaction system of human cells, the effects of IQ, Glu-P-1, Glu-P-2, Trp-P-l and Trp-P-2 were examined on human lymphocyte blast transformation induced by PHA. As shown in Table I, both Trp-P-l and Trp-P-2 strongly inhibited lymphocyte mitogenesis to PHA at the final concentration of 1.O-5.0 and 1.&lo ,uM, respectively. However, the other carcinogenic heterocyclic amines (IQ, Glu-P-1 and Glu-P-2) examined did not exhibit any inhibitory effect on lymphocyte blast transformation to PHA even at the final concentration of 10 ,uM. Trp-P-l showed the inhibitory effect more
230 TABLE’1 INHIBITORY
EFFECTS
LYMPHOCYTE
OF CARCINOGENIC
PROLIFERATION
INDUCED
HETEROCYCLIC
AMINES
ON THE
HUMAN
BY PHYTOHEMAGGLUTININ
Final
“/; Inhibition
concentration Trp-P- I
Trp-P-2
IQ
95.6k4.4
0.42
5.0
9X.7+9.2
49.2 & 3.2
2.5
31.4+ 7.8
32.254.0
9.8k2.5
27.71X.3
(/lM) IO.0
I .o Trp-P-1 indole; 3’2.d]
= 2-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole; IQ
=
Trp-P-2
2-amino-3-methylimidazo[4,5;1]quinolme;
imidazole;
Glu-P-2 = 2-aminodipyrido[
Glu-P-1
1,2-a:3’.2’-d]imidazole.
I.0
Glu-P- I
Cl&P-?
0.8 f 3.2
0.6 & 3.6
= 2-ammo-l-methyl-SH-pyrido[4,3-h]=
2-amino-6-methyldipyrido-[1,2-u:
Values represent
mean k SD for 5 ex-
periments.
strongly than Trp-P-2 and almost completely inhibited the lymphocyte response to PHA at the final concentration of 5 ,uM. The concentrations of Trp-P-l and Trp-P-2 causing 50% inhibition (I(&) of lymphocyte proliferation induced by PHA were estimated to be approximately 3.1 and 5.1 ,vM, respectively. Although it is unknown that the inhibitory effect of Trp-P-l and Trp-P-2 is actually taking place in vivo and is related to the carcinogenic action of these carcinogens, the fact that the carcinogens to which humans are actually exposed exhibit in vitro an inhibitory effect on the stimulussreaction system of human cells would be very interesting. Further studies are necessary for elucidating the mechanisms of the inhibitory effect on human lymphocyte blast transformation induced by PHA. ACKNOWLEDGEMENTS
We wish to thank Dr. Hisanori ma, Japan), for kindly providing FBT).
Matsumoto, Otsuka Assay Laboratories (Tokushithe lymphocyte blast transformation kit (JIMRO
REFERENCES 1 Doll, R. and Peto, R. (1981) The causes of cancer: in the United 2 Sugimura, process. 3 Grose,
States today.
J. Nat]. Cancer
T. (1985) Carcinogenicity Mutat.
K.R.,
estimates
of avoidable
risks of cancer
of mutagenic
heterocyclic
amines
formed
during
the cooking
Res. 150, 3341,
Grant,
tion of the carcinogen 4 Yamashita,
quantitative
Inst. 66, 1191ll308.
J.L., Bjeldances.
L.F., Andresen,
IQ from fried egg patties.
M., Wakabayashi,
K., Nagao,
M., Sate,
Tomita, I. and Sugimura, T. (1986) Detection rette smoke condensate. Gann 77,419422.
B.D. Felton,
J.S. and Hach,
F.T. (1986) Isola-
J. Agric. Food Chem. 34, 201l202. S., Yamaizumi,
Z., Takahashi,
of 2-amino-3-methylimidazo
M., Kinae,
[4,5,fl quinoline
N..
in ciga-
231
5 Yanagisawa,
H., Manabe,
S., Kitagawa,
Y., Ishikawa,
of 2-amino-3,8-dimethylimidazo[4,5-flquinoxaline Biophys.
Res. Commun.
6 Manabe,
S., Yanagisawa,
P-l and Trp-P-2, Mutat.
S., Nakajima,
in dialysate
0. (1986) Presence
with uremia.
Biochem.
138, 1084-1089 H., Guo, S.B., Abe, S., Ishikawa,
carcinogenic
tryptophan
pyrolysis
S. and Wada,
products,
0. (1987) Detection
in dialysis fluid of patients
of Trp-
with uremia.
Res. 179, 3340.
7 Yanagisawa,
H., Manabe,
fluid of uremic patients 8 Manabe,
S. and Wada, 0. (1987) Detection
treated
S., Yanagisawa,
by peritoneal
H., Ishikawa,
carcinogenic 6150-6155. 9 Yanagisawa, products Nephrol. 10 Ishikawa,
glutamic
acid pyrolysis
H., Manabe,
in the dialysate 30,73-78.
S., Kitagawa,
S., Manabe,
S., Kanai,
S., Yanagisawa,
effects of tryptophan
pyrolysis
glandin
synthetase.
endoperoxide
products,
Y., Kanai,
products
12 Itoh, Y., Fukamachi, ation of lymphocyte 21-22.
amines in dialysis
Y. and Wada,
0. (1987) Accumula-
treated
of patients
0. (1988) Carcinogenic
by continuous
H., Kitagawa, on human
with uremia.
Y., Kanai,
platelet
D.E., Murray,
ambulatory
glutamic peritoneal
Y. and Wada,
aggregation
Cancer
through
Res. 47,
acid pyrolysis dialysis.
Clin.
0. (1987) Inhibitory inhibition
of prosta-
25,8299835. N.L. and Evans, D.H. (1979) Ethidium
fluores-
studies, Nucleic Acids Res. 7, 5477568.
I., Nakajima, activation
in plasma
Food Chem. Toxicol.
A.R., Lee, J.S., Pulleyblank,
cence assays. I. Physicochemical
heterocyclic
29-9, 1153-l 159.
and 2-aminodipyrido[l,2-a:3’,2’-dimidazole,
Y. and Wada,
of uremic patients
of IQ-type
dialysis. Jpn. J. Nephrol.
tion of 2-amino-6-methyldipyrido[1,2-a:3’,2’-dimidazole
11 Morgan,
K. and Wada,
from patients
K., Kawai, T. and Nakano, by ethidium
bromide
K. (1983) A new method
fluorescence
assays.
for the evalu-
J. Clin. Exp. Med.
126,